Xifaxan (rifaximin) / Norgine, Alfa Wassermann, Lupin, ASKA Pharma, Bausch Health  >>  Phase 3
Welcome,         Profile    Billing    Logout  

5 Trials

   Remove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Xifaxan (rifaximin) / Alfa Wassermann, Bausch Health
2017-000488-34: Role of rifaximin in decreasing the circulating levels of endotoxin in patients with cirrhosis Ruolo della rifaximina per ridurre gli alti livelli sanguigni di endotossina nei pazienti affetti da cirrosi epatica

Not yet recruiting
3
40
Europe
RIFAXIMINA, n.a, Film-coated tablet, TIXTELLER - 550 MG COMPRESSE RIVESTITE CON FILM 14 COMPRESSE IN BLISTER PVC/PE/PVDC/AL
UMBERTO I - POLICLINICO DI ROMA, ALFA WASSERMANN S.p.A
PATIENTS WITH CIRRHOSIS CHILD PUGH B or C Classes PAZIENTI AFFETTI DA CIRROSI EPATICA CLASSE CHILD-PUGH B or C, ADVANCED CHRONIC LIVER DISEASE MALATTIA EPATICA CRONICA AVANZATA, Diseases [C] - Digestive System Diseases [C06]
 
 
2018-001891-39: Antibiotic treatment (Rifaxamin) of a chronic inflammatory diarrhoeal disease (Collagenous Colitis)

Ongoing
3
48
Europe
Xifaxan, Coated tablet, Xifaxan
XiCoCo study group, Norgine, Forskningsfonden Hospitalenhed Midt
Collagenous Colitis, Collagenous colitis is a chronic inflammatory diarrhoeal disease. The hypothesis is that supplemental treatment wit Xifaxan can lower the risk of relapse after discontinuation of standard treatment., Diseases [C] - Digestive System Diseases [C06]
 
 
ProPILARifax, NCT03069131: Two Strategies of Primary Prophylaxis of Spontaneous Bacterial Peritonitis in Severe Cirrhotic Patients With Ascites

Completed
3
160
Europe
Rifaximin, Placebo
Centre Hospitalier Universitaire de Besancon, Alfasigma S.p.A., LC2 PHARMA
Cirrhosis, Ascites, Peritonitis
06/22
03/23
RED-C-3131, NCT05071716: Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis

Active, not recruiting
3
524
Canada, US, RoW
Rifaximin SSD, Placebo
Bausch Health Americas, Inc.
Hepatic Encephalopathy
09/25
09/25
RED-C-3132, NCT05297448: Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis

Active, not recruiting
3
466
Europe, Canada, US, RoW
Rifaximin SSD, Placebo
Bausch Health Americas, Inc.
Hepatic Encephalopathy
01/26
01/26

Download Options